Cardiac disease monitoring measures in patients with transthyretin amyloid cardiomyopathy treated with tafamidis
NT-proBNP increase and ODI can serve as markers of WCD and predict mortality and CV hospitalisations in a cohort of patients taking tafamidis.
Authors
- Lawrence Zeldin (ORCID: https://orcid.org/0000-0002-3953-219X)
- Jonathan M. Levy (ORCID: https://orcid.org/0000-0002-8061-7953)
- Dia Smiley
- Mathew S. Maurer (ORCID: https://orcid.org/0000-0001-5400-5008)
- Dimitrios Bampatsias (ORCID: https://orcid.org/0000-0002-0415-2912)
- Sergio Luis Teruya
- Abdirahman Wardhere (ORCID: https://orcid.org/0009-0001-9303-6074)
- Ariel Weinsaft (ORCID: https://orcid.org/0000-0003-4778-9582)
- Alfonsina Mirabal-Santos
Institutions
- Columbia University Irving Medical Center (US)
Publication Details
- Journal
- Heart
- Published
- 2025-03-23
- DOI
- https://doi.org/10.1136/heartjnl-2024-324826
- Citations
- 6
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 4.84